KR880007514A - 키놀린 화합물 - Google Patents

키놀린 화합물 Download PDF

Info

Publication number
KR880007514A
KR880007514A KR870014675A KR870014675A KR880007514A KR 880007514 A KR880007514 A KR 880007514A KR 870014675 A KR870014675 A KR 870014675A KR 870014675 A KR870014675 A KR 870014675A KR 880007514 A KR880007514 A KR 880007514A
Authority
KR
South Korea
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
heart failure
Prior art date
Application number
KR870014675A
Other languages
English (en)
Inventor
페이지 필립스 아더
Original Assignee
원본미기재
더 웰컴 파운데이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 웰컴 파운데이션 리미티드 filed Critical 원본미기재
Publication of KR880007514A publication Critical patent/KR880007514A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Secondary Cells (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)

Abstract

내용 없음.

Description

키놀린 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 식(I)의 화합물 또는 그것의 약학적 허용염.
  2. 제1항에 있어서 식(I)화합물의 염화수소염.
  3. 제1항에 있어서, 인체 의학적 치료에 사용하기위한 식(I) 화합물 또는 그것의 약학적 허용염.
  4. 제1항에 있어서, 양성 근변력성제를 필요로하는 임상상태의 예방과 치료에 사용하기 위한 식(1) 화합물 또는 그것의 약학적 허용염.
  5. 제4항에 있어서, 혈관확장효과가 더욱 필요할때에 사용하기 위한 식(I) 화합물.
  6. 제4항 또는 제5항에 있어서, 임상상태가 심부전, 심근경색 또는 심장쇼크와 관계있는 울혈성 심부전 또는 심근질환일때 사용하기 위한 식(I)화합물.
  7. 양성 근변력성제를 필요로하는 임상상태의 예방과 치료를 위한 치료제의 제조시에, 제1항에서 청구한 바의 식(I) 화합물 또는 그것의 약학적 허용염의 사용방법.
  8. 제7항에 있어서 혈관확장효과가 더욱 필요할때의 사용방법.
  9. 제7항 또는 제8항에 있어서, 임상상태가 심부전, 심근경색 또는 심장쇼크와 관계있는 울혈성 심부전 또는 심근질환일때의 사용방법.
  10. 제1항에서 청구한바의 식(I)화합물 또는 그것의 약학적 허용염, 1이상의 약학적 허용담체 및 부형제, 그리고 임의로 1이상의 치료성분을 포함하는 약학제재.
  11. 하기식(Ⅱ)의 화합물과 하기식(Ⅲ)의 화합물을 염기의 존재하에서 반응시키고 필요에 따라 계속해서 형성된 식(Ⅰ) 화합물을 그것의 생리적 허용염으로 전환시키는 것으로 구성된 하기식(I)의 화합물 또는 그것의 약학적 허용염의 제조방법.
    (상기식에서 L과 L′는 같거나 다르며 이탈기가 적합하다)
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870014675A 1986-12-23 1987-12-22 키놀린 화합물 KR880007514A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8630702 1986-12-23
GB868630702A GB8630702D0 (en) 1986-12-23 1986-12-23 Quinoline compound

Publications (1)

Publication Number Publication Date
KR880007514A true KR880007514A (ko) 1988-08-27

Family

ID=10609475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870014675A KR880007514A (ko) 1986-12-23 1987-12-22 키놀린 화합물

Country Status (22)

Country Link
US (1) US4937248A (ko)
EP (1) EP0272910B1 (ko)
JP (1) JPS63166866A (ko)
KR (1) KR880007514A (ko)
AT (1) ATE65993T1 (ko)
AU (1) AU594220B2 (ko)
CA (1) CA1318671C (ko)
DE (1) DE3772015D1 (ko)
DK (1) DK163429C (ko)
ES (1) ES2029842T3 (ko)
FI (1) FI90768C (ko)
GB (1) GB8630702D0 (ko)
GR (1) GR3002445T3 (ko)
HU (1) HU196991B (ko)
IE (1) IE60619B1 (ko)
IL (1) IL84917A (ko)
MX (1) MX9203788A (ko)
MY (1) MY102277A (ko)
NZ (1) NZ223036A (ko)
PH (1) PH23448A (ko)
PT (1) PT86448B (ko)
ZA (1) ZA879615B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166160A (en) * 1986-12-23 1992-11-24 Burroughs Wellcome Co. Quinoline compound
GB8820174D0 (en) * 1988-08-25 1988-09-28 Wellcome Found Quinoline compound
AU735729B2 (en) * 1997-09-24 2001-07-12 Orion Corporation Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors
CZ2002711A3 (cs) 1999-08-27 2003-11-12 Ligand Pharmaceuticals Incorporated Modulátory androgenních receptorů, způsoby jejich výroby a způsoby jejich použití
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU6941200A (en) 1999-08-27 2001-03-26 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators
CA2383565A1 (en) 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004266160A1 (en) 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの調製方法
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616855A (en) * 1948-01-15 1952-11-04 Procter & Gamble Detergent composition
US4329347A (en) * 1978-02-17 1982-05-11 Boehringer Ingelheim Gmbh Cardiotonic and antithrombotic sulfur-containing derivatives of carbostyril
JPS5777676A (en) * 1980-10-31 1982-05-15 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4710507A (en) * 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
GR851296B (ko) * 1984-05-29 1985-11-25 Pfizer
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
US4845100A (en) * 1985-04-12 1989-07-04 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same
FR2580646A1 (fr) * 1985-04-19 1986-10-24 Synthelabo Derives de 2(1h)-quinolinone, leur preparation et leur application en therapeutique
GB8529362D0 (en) * 1985-11-28 1986-01-02 Pfizer Ltd Quinolone cardiac stimulants
DK111387A (da) * 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
ES2053480T3 (es) * 1986-07-31 1994-08-01 Otsuka Pharma Co Ltd Un procedimiento para preparar un derivado de carboestirilo.

Also Published As

Publication number Publication date
CA1318671C (en) 1993-06-01
DE3772015D1 (de) 1991-09-12
IL84917A0 (en) 1988-06-30
ES2029842T3 (es) 1992-10-01
MX9203788A (es) 1992-07-01
PH23448A (en) 1989-08-07
IE873490L (en) 1988-06-23
NZ223036A (en) 1990-11-27
PT86448B (pt) 1990-11-20
AU8293387A (en) 1988-06-23
DK163429C (da) 1992-07-20
FI90768C (fi) 1994-03-25
GR3002445T3 (en) 1992-12-30
FI90768B (fi) 1993-12-15
HU196991B (en) 1989-02-28
GB8630702D0 (en) 1987-02-04
EP0272910B1 (en) 1991-08-07
FI875666A0 (fi) 1987-12-22
ZA879615B (en) 1989-08-30
ATE65993T1 (de) 1991-08-15
EP0272910A1 (en) 1988-06-29
IL84917A (en) 1991-08-16
US4937248A (en) 1990-06-26
MY102277A (en) 1992-05-15
AU594220B2 (en) 1990-03-01
HUT45984A (en) 1988-09-28
DK680887A (da) 1988-06-24
IE60619B1 (en) 1994-07-27
JPS63166866A (ja) 1988-07-11
DK680887D0 (da) 1987-12-22
FI875666A (fi) 1988-06-24
PT86448A (en) 1988-01-01
DK163429B (da) 1992-03-02

Similar Documents

Publication Publication Date Title
KR880007514A (ko) 키놀린 화합물
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
DK275488A (da) Indolonderivater
KR880006206A (ko) 퀴나졸리논 유도체 및 이의 제조방법
DE3581699D1 (de) Bis-dimethoxymethyl(trimethoxybenzyl)isochinolinium-salze, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
KR910000158A (ko) 의약용 화합물 및 그것의 사용방법
ZA863382B (en) Quinolylglycinamide derivatives,the process for preparation thereof and their therapeutic application as psychotropic drugs
IL79910A (en) 5,7-dihydro-6-(thi)oxopyrrolo(2,3-f)benzimidazole,-benzothiazole and-benzoxazoles,6-imines thereof,their preparation and pharmaceutical compositions containing them
KR890012942A (ko) 5-치환된 오르니틴 유도체
EP0207483A3 (en) Benzimidazoles, process for their preparation, medicaments containing them and intermediates
KR960700711A (ko) 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
KR880006198A (ko) 2,6-디아미노-3- 할로벤질피리딘, 이의 제조방법 및 이의 약제학적 용도
KR880009943A (ko) 피리다지논 유도체
NZ220539A (en) 1,4-dihydropyridine derivatives and pharmaceutical compositions
KR920007626A (ko) 벤조[b]티오펜-2-카르복시이미드아미드 유도체의 사용방법
KR910000650A (ko) 사이클릭 안트라닐산 아세트산 유도체 및 이의 제조방법
KR960000224A (ko) 3, 7-디아자바이사이클로［3, 3, 1］노난- 화합물을 함유한 신규한 약제
KR880011077A (ko) 유효치료 물질로서 사용하기 위한 tert- 부틸아미노-3(페닐-2'-펜옥시)-1-프로판올-2 및 그의 산부가염
KR930004250A (ko) 치환된 1-페닐-1-벤조일아미노-5-아미노펜탄, 그의 제조 방법 및 용도
KR890001555A (ko) 요산 배설용 조성물
DK644487A (da) Farmaceutisk praeparat indeholdende en 2-oxo-imidazolidinforbindelse
KR920002139A (ko) 뇌혈관 수축 치료제
KR890017228A (ko) 부정맥치료제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application